Dr Lukas on Survival Outcomes With Eflornithine in IDH-Mutant Anaplastic Astrocytoma

Integrating HER3-DXd: Clinical Considerations for Future Approval and Implementation in Practice

Dr Elder on the Initial Safety Profile of IGV-001 in Newly Diagnosed Glioblastoma

Single-Agent Immune Therapy in UC: The Need for More

Key Takeaways for Concurrent Biomarker Testing in NSCLC

Dr Pant on the Importance of Targeted Therapy and Mutation Testing in Pancreatic Cancer

Dr Ecker on the Role of CAPETEM in the Treatment of Pancreatic NETs

Dr Garmezy on Findings From the Duravelo-1 Trial in Metastatic Urothelial Carcinoma

Future Directions in ALK-Positive and BRAF-Positive NSCLC Management

Discussion of RESORCE Trial

Outlining the Current First-Line Treatment Landscape in Metastatic Urothelial Cancer: Starting With a Cisplatin-Ineligible Patient Case

Real-World Treatment Data from the Phase 4 STELLAR Trial

Precision BRAF Therapy: Optimizing Dosing, Sequencing, and Toxicity Management in NSCLC

Dr Hochster on the Role of Cooperative Trials in Academic and Community Health Care Settings

Navigating mCRC: Treatment Options in the Third-Line Setting

Nuances With Defining “Refractory” mCRC in the Third-Line Setting

Dr Strickler on the Role of Biomarker Testing in Pancreatic Cancer

Dr Smaglo on the Evolution of RAS-Targeted Therapies for Pancreatic Cancer

Dr Pobel on the Prognostic Value of Phenotypic and Genomic Characterization in De Novo mCSPC

Dr O’Regan on Sequencing Considerations in Advanced HR+ Breast Cancer

Overview of PERSEUS, IsKia, and GMMG-HD7

Clinical Factors for Transplant Eligibility and Treatment Strategy in NDMM

Current Treatment Landscape of Newly Diagnosed Multiple Myeloma Patients